Diaverum is one of the world's leading renal care providers. Originally founded in Sweden, today it has 9,000 employees, caring for close to 30,000 patients in 20 countries in Europe, Latin America, Middle East/Asia and Australia.

Jiangsu Yueda Group Co., Ltd. is one of the top 520 state owned enterprises in China. It owns 2 listed companies and 30 subsidiary companies with about 40,000 employees and capital asset of over CNY 55 billion.

Diaverum and the Chinese Yueda Group has entered into a joint venture agreement aiming to provide renal care services in China.

The plan is to establish a nationwide network of dialysis centres that fills the current supply and quality gap in China. Like in many other countries worldwide, the management of chronic kidney disease presents a huge economic burden to the healthcare system in China with the patient numbers growing at high pace. The joint venture partnership aims to provide patients with Swedish and European high standards of renal care that is covered by Chinese public reimbursement schemes to make the service affordable.

Diaverum has been advised by Mannheimer Swartling in the transaction. The firm's team was led by Ulf Ohrling, primarily assisted by Simon Shi, Rachel Dong, Joanna Liu and Daria Yan.